Stakeholder Call: COVID-19 Testing Update – 3/1/2021
Acting FDA Commissioner, Janet Woodcock, M.D., and Jeff Shuren, M.D., J.D., Director, Center for Devices and Radiological Health, provide updates on recent work and host a question and answer session on #COVID19 testing.
Видео Stakeholder Call: COVID-19 Testing Update – 3/1/2021 канала U.S. Food and Drug Administration
Видео Stakeholder Call: COVID-19 Testing Update – 3/1/2021 канала U.S. Food and Drug Administration
Показать
Комментарии отсутствуют
Информация о видео
11 марта 2021 г. 23:26:45
00:35:01
Другие видео канала
Changes to Orange Book Patent Information
Natural History Studies for Rare Diseases
Public Meeting: Patient-Focused Drug Development for Chronic Pain (Part 1)
Diversity in Clinical Trials: Learn about Enrollment Trends and Resources from FDA
LASIK Surgery and its Risks
Health Equity and COVID-19: What Minority Communities Need to Know
Drug Substance Postapproval Changes Guidance: Determination of Impurity Profile Equivalence
FDA Study Data Technical Conformance Guide v4.4 - Nov 22, 2019
FDA's Role in Improving Nutrition: Labeling and Other Authorities
Overview of the Guidance for Industry: Control of Nitrosamine Impurities in Human Drugs
Virtual Press Conference: First COVID-19 Vaccine - 12/12/2020
How to Update Orange Book Information
Public Meeting: Patient-Focused Drug Development for Systemic Sclerosis
Medication Guides: Distribution Requirements for Health Care Professionals
Risk Evaluation and Mitigation Strategies (REMS) Compliance Program
New Approaches for an Integrated Nonclinical-Clinical QT/Proarrhythmic Risk Assessment (1 of 2)
Vaccines and Related Biological Products Advisory Committee – 2/26/2021
Dina Zand's Work on Rare Diseases
Nitrosamines: Where Are We Now?
FDA Safety Report Type Flag Requirement for FAERS Submissions